Boston, MA 06/17/2014 (wallstreetpr) – Novogen Limited (ADR) (NASDAQ:NVGN) is high today thanks to the positive results on its experimental ovarian cancer treatment. The company has announced that it expects to file with regulators in early 2015 so that it can start Phase 1 study of the treatment by mid-2015.
The company is developing an ovarian cancer treatment in collaboration with Yale University through a joint venture known as CanTx Inc. The latest data on the treatment were issued during the ongoing Drug Discovery and Therapy 2014 World Congress in Boston.
The companies have tried the drug in an animal model and found it potent in combating the ovarian cancer. They believe the drug can do just as well in human, and they intend to launch a study of the drug in human soon after receiving regulatory approval.
The experimental drug, which is currently known as Trx-1, passed a proof-of-concept pre-clinical study, and the developers believe that could provide a breakthrough in the primary treatment of ovarian cancer. As a matter of fact, developers say it could be utilized as first-line therapy on ovarian cancer patients.
Its ability has been noted in killing the chemo-resistant ovarian cancer stem cells. The data provided by researchers show that the drug can significantly hinder the growth of ovarian cancer stem cells.
Successful pre-clinical trial
It is also worth noting that the developers said the treatment showed compelling success in pre-clinical study an animal model that is highly representative of a human situation. In other words, Novogen believes that the treatment will be as successful in humans as it has been noted at the pre-clinical level. However, future results from clinical trials should support that position if the drug is to find its way to the market.
In any case, ovarian cancer is considered one of the most lethal types of cancer, which means that the compelling success of the proposed treatment in the upcoming trials might earn its various drug development privileges to speed up its development.
Toward commercialization
Novogen Limited (ADR) (NASDAQ:NVGN) and its partner Yale University intend to apply for an Investigational New Drug with the U.S. Food and Drug Administration (FDA) early next year after which they expect to commence Phase 1 clinical trial in mid-2015.
